Efficacy and tolerability of fixed-combination bimatoprost/timolol versus fixed-combination dorzolamide/brimonidine/timolol in patients with primary open-angle glaucoma or ocular hypertension: a multicenter, prospective, crossover study by unknown
García-López et al. BMC Ophthalmology 2014, 14:161
http://www.biomedcentral.com/1471-2415/14/161RESEARCH ARTICLE Open AccessEfficacy and tolerability of fixed-combination
bimatoprost/timolol versus fixed-combination
dorzolamide/brimonidine/timolol in patients
with primary open-angle glaucoma or ocular
hypertension: a multicenter, prospective,
crossover study
Alfonso García-López1*, José A Paczka2,3, Jesús Jiménez-Román4 and Curt Hartleben5Abstract
Background: Fixed-combination ocular hypotensives have multiple advantages, but triple-therapy dorzolamide/
brimonidine/timolol (dorz/brim/tim) is only available in Latin and South America, and information on its relative
efficacy is limited. This study compares the efficacy and tolerability of fixed-combination bimatoprost/timolol
(bim/tim) and dorz/brim/tim in Mexican patients with primary open-angle glaucoma or ocular hypertension.
Methods: In this investigator-masked, crossover study, patients with unmet target intraocular pressure (IOP) on
once-daily bim/tim or twice-daily dorz/brim/tim received the opposite medication for 3 months before returning
to their pre-baseline medication for 3 months. IOP was evaluated before and after morning instillation at months
2, 3, 5 and 6. Primary endpoints were mean IOP change and Ocular Surface Disease Index© (OSDI) score at each visit.
The intent-to-treat population was the a priori analysis population, but due to the number of discontinuations, the
per-protocol and intent-to-treat populations were used for the primary efficacy and sensitivity analyses, respectively.
Results: Seventy-eight and 56 patients were included in the intent-to-treat and per-protocol populations, respectively.
At month 3, statistically significant IOP reductions from baseline were observed in the bim/tim (P < 0.01) and dorz/
brim/tim (P < 0.0001) groups, regardless of assessment time. At month 6, patients returned to bim/tim exhibited no
significant IOP increase (regardless of assessment time), but patients returned to dorz/brim/tim exhibited a statistically
significant IOP increase (P < 0.001) when assessed before instillation of study treatment. Results were similar in both
intent-to-treat and per-protocol analysis populations. In the per-protocol analysis, 70% of patients on bim/tim at month
3 had an IOP <14 mm Hg, which declined to 58% (P = 0.0061) at month 6 (ie, after 3 months of dorz/brim/tim
treatment). In patients receiving dorz/brim/tim at month 3, 38% had an IOP <14 mm Hg, which remained comparable
after return to bim/tim. OSDI scores and incidence of adverse events were similar in both groups.
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Conclusions: In this first direct comparison of the efficacy of dorz/brim/tim and bim/tim, patients switched from dorz/
brim/tim to bim/tim demonstrated improved/lower IOP; when returned to dorz/brim/tim, IOP increased to levels seen
at study initiation, suggesting that once-daily bim/tim may have greater IOP-lowering efficacy. Both bim/tim and dorz/
brim/tim were well tolerated with minimal ocular surface damage.
Trial registration: ClinicalTrials.gov: NCT01737853 (registered October 9, 2012)
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Glaucoma is a leading cause of blindness worldwide,
with prevalence varying across different populations [1].
Latin Americans, especially those of Mexican origin, are
prone to develop primary open-angle glaucoma (POAG),
compared with Whites [2-4], and an increase in intraoc-
ular pressure (IOP) raises the risk that individuals with
ocular hypertension (OHT) will develop POAG [5,6],
and that those with glaucoma will experience further
progression [7,8]. Consequently, treatment of glaucoma
and OHT focuses mainly on lowering IOP [9,10].
Options for medical therapy have expanded over the last
2 decades; beta-adrenoceptor antagonist and prostaglan-
din analog/prostamide monotherapies are used as first-
line treatment [11] while alpha-2 adrenoceptor agonists,
parasympathomimetics, and topical carbonic anhydrase
inhibitors are used as second-line options [9,10]. The
introduction of these new classes of IOP-lowering drugs
has contributed to challenges for prescribers, as a suitable
agent depends not only on its IOP-lowering capacity, but
also on its tolerability and convenience of use [12].
Monotherapy is the recommended initial approach for
glaucoma treatment [13-15], but combinations of agents
are often necessary [16-18]. A recently published sys-
tematic review and meta-analysis of 5 studies comparing
fixed and unfixed combinations of timolol and a prosta-
glandin analog found that fixed combinations were less
effective in reducing IOP than unfixed combinations
[19]. However, statistical heterogeneity analysis suggested
that this observed effect was likely due to differences in
study design and conduct, and not chance alone (I2 = 52%).
Fixed-combination hypotensive therapies do have advan-
tages of limiting preservative-related adverse effects and
producing lower rates of hyperemia [19], and have the po-
tential to increase adherence and reduce costs [12,18,20].
The majority of non-prostaglandin analog-based fixed
combinations available are dual, timolol-containing therap-
ies. An exception is the triple-combination of dorzolamide
2%, brimonidine 0.2%, and timolol maleate 0.5% (dorz/
brim/tim; Krytantek®; Laboratorios Sophia, Guadalajara,
Mexico), which is only available in Latin and South
American countries. Reports on the clinical properties of
this 3-drug combination are limited [21,22]. In contrast,
the efficacy and safety of the commonly used fixedcombination of bimatoprost 0.03% and timolol maleate
0.5% (bim/tim; Ganfort®; Ganforti®; Allergan, Inc., Irvine,
CA, USA) has been studied extensively [23-32].
The objective of this clinical trial was to compare the
efficacy and tolerability of once-daily bim/tim with twice-
daily dorz/brim/tim over a 6-month period, using a cross-
over study design in patients with POAG or OHT who
had not reached target IOP.Methods
This phase 4, 6-month, prospective, multicenter, investigator-
masked, crossover study (ClinicalTrials.gov Identifier:
NCT01737853 [registered Oct. 9, 2012]) comprised 2
treatment periods of 3 months each (Figure 1). Patients
were enrolled between February 2011 and June 2012 at
4 centers in Mexico, after the study protocol was approved
by the Hospital Fundación Nuestra Señora de la Luz Eth-
ics Committee for all study sites. The study was conducted
in accordance with Good Clinical Practice guidelines, as
well as all applicable local laws. Patients (or their legal
guardian) signed an informed consent prior to study
initiation.Study participants
Patients attended an initial screening visit for assessment
of inclusion and exclusion criteria. The study recruited
patients >17 years of age with a diagnosis of mild to
moderate POAG or OHT who had failed to reach target
IOP despite receiving bim/tim or dorz/brim/tim for at
least 1 month. Patients were required to have an IOP ≥18
and ≤36 mm Hg, as well as a best-corrected visual acuity
of at least 20/80 in both eyes. Women of reproductive age
were required to use a reliable method of contraception
during the study period. Exclusion criteria were: any ocu-
lar disorder other than mild to moderate loss of lens trans-
parency, glaucoma or OHT; significant visual field loss
in the previous year; uncontrolled systemic disease; ac-
tive ocular disease, or intraocular surgery within the
past 3 months; use of other medications with a poten-
tial substantial effect on IOP; allergy or other contrain-
dications to any components of the study product; and




















































Figure 1 Study design. No assessments were performed at months 1 and 4. Bim/tim, bimatoprost 0.03% and timolol maleate 0.5%; dorz/brim/
tim, dorzolamide 2%, brimonidine 0.2%, and timolol maleate 0.5%; IOP, intraocular pressure.
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Eligible patients who had received dorz/brim/tim for
≥1 month prior to the baseline visit (group 1) were
assigned to receive bim/tim for 3 months, and those
who had received bim/tim for ≥1 month prior to the
baseline visit (group 2) were assigned to receive dorz/
brim/tim for 3 months (Figure 1). At the 3-month visit,
patients were reassigned to the study medication they
had been receiving before the baseline crossover for 3
additional months. Bim/tim was administered once daily
at 8 AM and dorz/brim/tim was administered twice daily
at 8 AM and 8 PM. The investigators were masked to the
instillation schedule.
Bottles of study medication were dispensed to the pa-
tient in a closed, labeled box by an office assistant, and
were returned in the same box to the assigned office as-
sistant, but never to the principal investigator or sub-
investigator in order to preserve the single-masked nature
of the study. Study medication bottles were dispensed at
the baseline visit and monthly thereafter. Patients received
verbal instructions, written reminders, and periodic phone
calls to promote adherence to medication.
Assessment visits were scheduled at baseline, months 2
and 3 during the first treatment period, and months 5 and
6 during the second treatment period (Figure 1). There
were no assessments at months 1 and 4 (considered the
run-in phases after each crossover). At baseline and
study end, IOP, visual acuity, refraction and visual field
(Humphrey 24–2) were evaluated, and central ultra-
sound pachymetry, gonioscopy, and dilated funduscopy
were performed. IOP assessments were performed
(using a Goldmann applanation tonometer) at 8 AM
and 10 AM (ie, before and after morning instillation of
the study drug) and recorded at each visit, along with
Ocular Surface Disease Index© (OSDI) [34], slit-lamp bio-
microscopy, blood pressure, pulse, and adverse events.Since IOP was a main study endpoint, particular care was
taken to obtain unbiased measurements using a 2-person
method in which one adjusts the dial in a masked fashion
and the second reads and records the value. IOP was mea-
sured twice consecutively; if the difference between mea-
surements was >2 mm Hg, a third measurement was
taken, and the mean of all 3 measurements was recorded.
Data analysis and sample size calculation
The primary endpoints were mean IOP reduction (at 8
AM and 10 AM) and OSDI scores at each visit. The
intent-to-treat (ITT) population was the a priori analysis
population, but due to the considerable number of discon-
tinuations, the per-protocol (PP) population was used for
the primary efficacy and OSDI analyses, and the ITT
population was used for sensitivity analyses. For patients
with a bilateral condition, data for a randomly chosen eye
were included in the analyses.
Analyses of mean IOP and differences in IOP reduc-
tion between treatment arms were performed using a re-
peated analysis of variance. Intra-group comparisons of
values at baseline and subsequent time-points were con-
ducted using a 2-tailed, paired Student t test. A Bonferroni
post hoc correction was used to adjust the P value for in-
dividual time-points. The percentage of patients with IOP
control at baseline and months 3 and 6 (10 AM assess-
ment) was calculated for each of the treatment arms,
based on IOP level (<14, <18, and <21 mm Hg). A chi-
square distribution test was used to determine the statis-
tical significance of the change in percentage in the
response analysis. The Student t test and a nonparametric
chi-square test were used to analyze between-group differ-
ences in OSDI scores and adverse events, respectively, at
each time-point in the ITT population.
Enrollment of 90 patients was planned (45 per treat-
ment arm) to ensure approximately 80 evaluable patients
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into account the following assumptions: a standardized
effect size of 0.60, a 2-sided α value of 0.01, and a β
value of 0.10.
Results
Ninety-two patients were screened and 85 enrolled; 7
patients did not meet the eligibility criteria at baseline.
Of the 78 patients who received 1 dose of study medication
(ITT population), 22 discontinued early. Reasons recorded
were nonadherence to therapy (n = 10), unwillingness to
participate (n = 6), or the following adverse events: 3 pa-
tients with severe hyperemia or sensation of foreign body
while receiving bim/tim, 2 patients with severe hyperemia
or reduced visual field (caused by treatment-unrelated
cerebrovascular disease; the patient recovered total visual
capacity after 48 hours) while receiving dorz/brim/tim; 1
patient with an unspecified adverse event. Fifty-six patients
comprised the PP population. Patient demographics and
characteristics are presented in Table 1. Mean age ±
standard deviation was 66 ± 10 years (range: 46–93), the
majority of patients were female, and 62% had a diagno-
sis of POAG.
In the PP population, patients who received bim/tim
for the first 3 months (group 1) had a mean baseline
IOP of 19.5 ± 2.1 mm Hg at 8 AM and 18.3 ± 2.6 mm Hg
at 10 AM. At the 3-month visit, mean IOP was reduced
to 14.6 ± 3.8 mm Hg at 8 AM and 13.6 mm Hg ± 2.8 at
10 AM (Table 2). Patients who received dorz/brim/tim
for the first 3 months (group 2) had a mean baseline
IOP of 20.2 ± 2.5 and 19.4 ± 1.9 mm Hg at 8 AM and
10 AM, respectively. At the 3-month visit, mean IOP
was reduced to 16.9 ± 3.7 and 15.7 ± 2.9 mm Hg at 8 AM
and 10 AM, respectively (Table 2). Statistically significant
IOP reductions from baseline were observed in both groups
at the month 3 visit, regardless of the assessment time
(Table 3).
When patients assigned to bim/tim at baseline were






Mean age, years (SD) 66 (10) 66 (10)
Female, n (%) 64 (82) 46 (82)
Race
Hispanic, n (%) 78 (100) 56 (100)
Baseline IOP, mm Hg (SD) 19.5 (2.2) 19.5 (2.1)
BCVA, letters (SD) 0.3 (0.3) 0.2 (0.3)
Corneal thickness, μm 545 ± 36 540 ± 36
BCVA, best-corrected visual acuity; ITT, intent-to-treat; OHT, ocular hypertension;
POAG, primary open-angle glaucoma; PP, per-protocol; SD, standard deviation.IOP at 8 AM increased from 14.6 ± 3.8 mm Hg to 17.6 ±
3.4 mm Hg at the 6-month visit, but remained stable at
10 AM (13.6 ± 2.8 to 13.8 ± 3.1 mm Hg, respectively).
When patients assigned to dorz/brim/tim at baseline
were switched to bim/tim at 3 months (group 2), IOP
was relatively stable up to month 6 (Tables 2 and 3). Im-
portantly, similar results were observed in the ITT
population (Figures 2A-B, 3A-B, and Tables 2 and 3).
When the change in IOP observed during the second
crossover period was analyzed by visit and measurement
time, mean IOP significantly increased from months 3 to
5 in all but the dorz/brim/tim group at 10 AM; from
months 5 to 6, there was a statistically significant decrease
in IOP in the bim/tim-treated group at both 8 and 10 AM
(Table 4). However, a similar analysis in the ITT popula-
tion did not reveal any statistically significant changes in
IOP between visits.
From baseline to month 3, there were statistically
significant increases in the percentage of patients with
IOP <14 mm Hg and <18 mm Hg among those receiv-
ing bim/tim (group 1) and dorz/brim/tim (group 2)
(Table 5). Notably, similar responses were observed in
the ITT population. Between months 3 and 6, there
was a statistically significant decline in the percentage
of patients with IOP <14 mm Hg and <18 mm Hg after
switching from bim/tim to dorz/brim/tim (P ≤ 0.0061) in
both the PP and ITT populations. In contrast, there was
no such decline after patients switched from dorz/brim/
tim to bim/tim (Table 5). During the first treatment
period, the percentage of patients with IOP <14 mm Hg
while receiving bim/tim was almost twice that of patients
receiving dorz/brim/tim. During the second treatment
period, this difference in response was somewhat main-
tained, favoring patients receiving dorz/brim/tim (Table 5).
Overall, the response to bim/tim and dorz/brim/tim was
significantly different from baseline to month 3 and from
months 3 to 6 (P ≤ 0.014 and P ≤ 0.008, respectively) in
both the PP and ITTanalyses.
During the course of the study, OSDI scores were
similar in both treatment arms (Figure 4). Of note, al-
though still in the normal range, the mean baseline score
in patients receiving dorz/brim/tim prior to the baseline
crossover was higher than in those receiving bim/tim
and tended to increase over time.
Few adverse events were reported during the study,
with severe hyperemia being the most common and the
only one that was treatment-related (Table 6). Other-
wise, cup/disk ratio and visual field were not statistically
different between treatment groups. Cup/disk ratios
were 0.63 vs 0.65 at baseline, and 0.63 vs 0.64 at the final
visit for groups 1 (P = 0.46) and 2 (P = 0.75), respectively.
Similarly, pattern standard deviation was 4.03 vs 4.06 at
baseline, and 4.44 vs 4.38 at the final visit for groups 1
(P = 0.96) and 2 (P = 0.91), respectively.
Table 2 Comparison of the mean intraocular pressure at each assessment visit in the per-protocol and intent-to-treat populations
Per-protocol population
Treatment group/time-point (baseline) Mean IOP ± SD (mm Hg) n Treatment group/time-point (crossover) Mean IOP ± SD (mm Hg) n
Baseline Month 2 Month 3 Month 5 Month 6
Bim/tim 8 AM 19.5 ± 2.1 15.9 ± 3.6 14.6 ± 3.8 30 Dorz/brim/tim 8 AM 16.6 ± 4.0 17.6 ± 3.4 30
Bim/tim 10 AM 18.3 ± 2.6 14.2 ± 3.1 13.6 ± 2.8 Dorz/brim/tim 10 AM 13.3 ± 3.2 13.8 ± 3.1
Dorz/brim/tim 8 AM 20.2 ± 2.5 17.1 ± 3.4 16.9 ± 3.7 26 Bim/tim 8 AM 17.0 ± 3.3 16.0 ± 2.9 26
Dorz/brim/tim 10 AM 19.4 ± 1.9 15.8 ± 2.9 15.7 ± 2.9 Bim/tim 10 AM 16.0 ± 2.9 15.6 ± 2.3
Intent-to-treat population
Treatment group/time-point (baseline) Baseline Month 2 Month 3 n Treatment group/time-point (crossover) Month 5 Month 6 n
Bim/tim 8 AM 19.5 ± 2.2 16.1 ± 3.4 14.8 ± 3.5 41 (BL)–35 (M3) Dorz/brim/tim 8 AM 16.5 ± 3.8 17.7 ± 3.4 35 (M3)–26 (M6)
Bim/tim 10 AM 18.1 ± 2.7 14.5 ± 2.3 13.7 ± 2.3 Dorz/brim/tim 10 AM 13.3 ± 3.0 14.1 ± 3.3
Dorz/brim/tim 8 AM 19.8 ± 2.3 16.8 ± 3.7 16.7 ± 3.7 37 (BL)–28 (M3) Bim/tim 8 AM 16.7 ± 3.3 16.6 ± 2.9 28 (M3)–32 (M6)
Dorz/brim/tim 10 AM 18.6 ± 2.9 15.3 ± 2.6 15.6 ± 2.9 Bim/tim 10 AM 15.7 ± 3.1 15.6 ± 2.3




















Table 3 Differences in mean intraocular pressure with each treatment
Per-protocol population
Treatment group/time-point (baseline) Baseline-month 3 Treatment group/time-point (crossover) Month 3-month 6
mm Hg ± SD P value* n mm Hg ± SD P value* n
Bim/tim 8 AM −4.9 ± 1.7 0.0073 30 Dorz/brim/tim 8 AM +3.0 ± 0.4 0.0006 30
Bim/tim 10 AM −4.7 ± 0.2 0.0045 Dorz/brim/tim 10 AM +0.2 ± 0.3 0.2710
Dorz/brim/tim 8 AM −3.3 ± 1.2 <0.0001 26 Bim/tim 8 AM −0.9 ± 0.8 0.0770 26
Dorz/brim/tim 10 AM −3.0 ± 1.0 <0.0001 Bim/tim 10 AM 0.0 ± 0.6 0.9463
Intent-to-treat population
Treatment group/time-point (baseline) Baseline-month 3 Treatment group/time-point (crossover) Month 3-month 6
mm Hg ± SD P value* n mm Hg ± SD P value* n
Bim/tim 8 AM −4.7 ± 1.3 <0.0001 41 (BL)–35 (M3) Dorz/brim/tim 8 AM +2.9 ± 2.9 0.0006 35 (M3)–26 (M6)
Bim/tim 10 AM −4.4 ± 0.4 <0.0001 Dorz/brim/tim 10 AM +0.3 ± 0.3 0.5940
Dorz/brim/tim 8 AM −3.1 ± 1.3 <0.0001 37 (BL)–28 (M3) Bim/tim 8 AM −0.1 ± 0.8 0.9286 28 (M3)–32 (M6)
Dorz/brim/tim 10 AM −3.0 ± 0.0 <0.0001 Bim/tim 10 AM 0.0 ± 0.6 0.9463
*Student t test.





























































































Figure 2 Mean IOP at baseline, month 2, and month 3 following the baseline crossover (ITT population). A. Mean IOP ± SD in Group 1.
B. Mean IOP ± SD in Group 2. Bim/tim, bimatoprost 0.03% and timolol maleate 0.5%; dorz/brim/tim, dorzolamide 2%, brimonidine 0.2%, and timolol
maleate 0.5%; IOP, intraocular pressure; ITT, intent-to-treat; SD, standard deviation.
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In patients with POAG or OHT and inadequate IOP
control on once-daily bim/tim or twice-daily dorz/brim/
tim, significant IOP reductions from baseline were pro-
duced over a 3-month period when transitioned to the
opposite therapy. However, bim/tim demonstrated better
IOP reduction at peak (10 AM) and trough (8 AM) than
dorz/brim/tim. At the end of the second treatment
period (ie, month 6), when treatment was returned to
the combination used prior to the baseline crossover,
nonsignificant IOP reductions from month-3 were seen
at both peak and trough in patients receiving bim/tim.
In contrast, patients receiving dorz/brim/tim experienced
an IOP increase at trough between both months 3 and 5,
and 5 and 6, most likely due to the pharmacokinetics of
dorz/brim/tim itself. During the first treatment period,
a significant percentage of patients achieved an IOP re-
sponse <14 mm Hg in both treatment groups, compared
with baseline, but the percentage was almost twice as
high in the bim/tim group. In addition, the level of IOP
lowering was maintained in patients switched from
dorz/brim/tim to bim/tim during the second treatment
period. Importantly, findings of the primary efficacy and
OSDI analyses were confirmed in a sensitivity analysis
using the ITT population.Clinicians have become increasingly interested in the
effects of topical treatments on the condition of the ocu-
lar surface in patients with glaucoma and OHT. Chronic
use of eye drops, particularly multidose products that
contain preservatives, has been associated with damage
to the ocular surface owing to the inherent toxicity of
some preservatives and drugs [35-38]. As demonstrated
by the low OSDI scores (the gold standard measure of
ocular surface damage [34]), both bim/tim and dorz/
brim/tim had minimal, if any, detrimental effects on the
ocular surface. OSDI scores of patients who entered the
study on dorz/brim/tim tended to increase slightly over
time, especially during the first treatment period. The
underlying reason is unclear as the OSDI score remained
relatively stable after a similar switch from dorz/brim/
tim to bim/tim in patients receiving bim/tim prior to the
baseline crossover.
Treatment of glaucoma or OHT aims to lower IOP and
preserve visual function. The benefits of lowering IOP in
delaying or preventing disease progression are well docu-
mented [9,39-41]. A Canadian observational study has
shown that in patients with progressive disease, a 20% re-
duction in median IOP was associated with a 69% reduc-
tion in the median rate of visual field decline [42]. A large










































































Figure 3 Mean IOP at months 3, 5 and 6 following the 3-month crossover (ITT population). A. Mean IOP ± SD in Group 1. B. Mean IOP ±
SD in Group 2. Bim/tim, bimatoprost 0.03% and timolol maleate 0.5%; dorz/brim/tim, dorzolamide 2%, brimonidine 0.2%, and timolol maleate
0.5%; IOP, intraocular pressure; ITT, intent-to-treat; SD, standard deviation.
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IOP-lowering capacity, but also on its tolerability and con-
venience of use. The advantages of fixed-combination
treatments such as bim/tim and dorz/brim/tim over
unfixed combinations (ie, multiple single agents used con-
comitantly) are well known [43,44], but information on
the relative efficacy of dorz/brim/tim is limited. The find-
ings of our study suggest that bim/tim may offer benefits
over dorz/brim/tim in terms of IOP lowering. The once-
daily administration of bim/tim may also be more conveni-
ent for patients and thus lead to improved adherence to
therapy [45], although neither convenience nor adherenceTable 4 Differences in mean intraocular pressure between vis
Per-protocol p
Treatment group/time-point Month 3-month 5
mm Hg ± SD P va
Dorz/brim/tim 8 AM +2.0 ± 0.2 0.
Dorz/brim/tim 10 AM −0.3 ± 0.4 0.
Bim/tim 8 AM +0.1 ± 0.4 0.
Bim/tim 10 AM +0.3 ± 0.1 0.
*Student t test.
Bim/tim, bimatoprost 0.03% and timolol maleate 0.5%; dorz/brim/tim, dorzolamide 2was evaluated in this study. In future studies, the increase
in IOP observed with dorz/brim/tim after the second cross-
over is a phenomenon that should be investigated. More-
over, the longer-term effects of dorz/brim/tim on IOP
should be evaluated to determine the advantages and disad-
vantages of this combination in the treatment of patients
with chronic open-angle glaucoma.
Since low diastolic blood pressure and diastolic ocular
perfusion pressure have also been reported as risk factors
for the development and progression of POAG [3,46-49],
the effect of topical IOP-lowering therapies on these vari-
ables has been investigated. Two randomized clinicalits during the second crossover period
opulation
Month 5-month 6 n
lue* mm Hg ± SD P value*
004 +1.0 ± 0.5 0.035 30
036 +0.5 ± 0.1 0.031
007 −1.0 ± 0.4 0.003 26
031 −0.4 ± 0.5 0.015
%, brimonidine 0.2%, and timolol maleate 0.5%; SD, standard deviation.
Table 5 Response to treatment by level of IOP
Per-protocol population
IOP level













Baseline Month 3 Month 6
<14 Bim/tim (group 1) 3 70 <0.00001 Dorz/brim/tim (group 1) 58 0.0061 30
<18 31 100 93
<21 95 100 100
<14 Dorz/brim/tim
(group 2)
0 38 <0.0001 Bim/tim (group 2) 33 0.1778 26
<18 30 93 87
<21 85 98 96
*The presence of patients in the <14 and <18 mm Hg categories at baseline is due to the fact that baseline IOP was assessed at 8 AM (ie, before instillation)
whereas response to treatment was based on IOP measurements taken at 10 AM (ie, 2 hours post-instillation).
†2-tailed, chi-square distribution.
Bim/tim, bimatoprost 0.03% and timolol maleate 0.5%; dorz/brim/tim, dorzolamide 2%, brimonidine 0.2%, and timolol maleate 0.5%; IOP: Intraocular pressure.
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history of cardiovascular disease found that timolol and
brimonidine monotherapies, and fixed-combination timo-
lol/dorzolamide significantly decreased diastolic blood
pressure over 24 hours; dorzolamide or latanoprost alone
had either no or opposite effects on blood pressure, and
increased calculated diastolic ocular perfusion pressure
[50,51]. A later, similarly designed study reported that























































Figure 4 Mean OSDI scores over the course of the study (n = 78). The
in either group (P > 0.1). Bim/tim, bimatoprost 0.03% and timolol maleate 0
maleate 0.5%; OSDI, Ocular Surface Disease Index; SE, standard error.calculated ocular perfusion pressure [52], suggesting that
additional, long-term confirmatory research is needed.
Nevertheless, these studies appear to support a better risk-
to-benefit ratio for bim/tim than for dorz/brim/tim in the
present study.
A particular strength of our study is the use of a
crossover design, which minimizes the impact of con-
founding covariates while requiring fewer patients to











change in OSDI score (± SE) over time was not statistically significant
.5%; dorz/brim/tim, dorzolamide 2%, brimonidine 0.2%, and timolol
Table 6 Adverse events reported during the study (N = 78)
Adverse event Cases Withdrawals Treatment at the time of withdrawal*
Vitreous hemorrhage 1 0
Pruritus 1 0
Severe hyperemia 3 3 bim/tim (2), dorz/brim/tim (1)
Sensation of foreign body and conjunctival edema 1 1 bim/tim
Severe eyelid edema 1 0
Reduced visual field 1 1 dorz/brim/tim
Allergy 1 0
Significantly reduced vision 1 0
Blurred vision 1 0
Not specified 1 1 dorz/brim/tim
Total 12 6
*Refers to the study medication taken at the time of withdrawal, but does not indicate that the adverse event was treatment-related.
Nonparametric chi-square test, P = 0.202.
Bim/tim, bimatoprost 0.03% and timolol maleate 0.5%; dorz/brim/tim, dorzolamide 2%, brimonidine 0.2%, and timolol maleate 0.5%.
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http://www.biomedcentral.com/1471-2415/14/161[53,54]. Nevertheless, crossover trials have some recog-
nized disadvantages, such as the potential for carryover ef-
fects between treatments. In our study, however, the
potential for carryover effects was addressed by including
a wash-in period and initiating assessment of outcome
variables 2 months after the first crossover (month 3) and
second crossover (month 5) of study medications. Another
potential weakness relates to the considerable number of
discontinuations recorded over the course of the study.
Although we cannot exclude the possibility that patients
who discontinued because of nonadherence or unwilling-
ness to participate did so after experiencing adverse
events, our calculations indicated that a 95% confidence
level would have required a total of 74 patients, whereas
39 patients would suffice to attain a 90% confidence level.
We can thus conclude that the number of discontinuations
did not limit the statistical significance of our findings or
the study conclusions.Conclusions
Topical combination therapies are often necessary to
prevent onset or progression of glaucoma, and fixed-
combinations are advantageous over concomitant sin-
gle agents. To the best of our knowledge, this is the
first, direct comparison of fixed-combination dorz/
brim/tim and bim/tim published. In patients with
POAG or OHT and inadequate IOP control, both
once-daily bim/tim and twice-daily dorz/brim/tim re-
duced IOP, although once-daily bim/tim appeared to
offer greater IOP-lowering efficacy. Bim/tim and dorz/
brim/tim were well tolerated and had minimal (if any)
detrimental effects on the ocular surface. Further stud-
ies are needed to compare the longer-term effects onocular surface and adherence, especially given the
twice-daily dosing regimen of dorz/brim/tim.Abbreviations
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